Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma

2018/02/28 by J.M. Moskovitz, Jessica Moskovitz, R.L. Ferris +1 · 16 citations
Medicine · Immunology and Microbiology · #Cancer Immunotherapy and Biomarkers #Immunotherapy and Immune Responses #Immune Cell Function and Interaction

paper · doi:10.1177/0022034518759464

Abstract

The immune system plays an important role in the evolution of malignancy and has become an important target for novel antineoplastic agents. This review article focuses on key features of tumor immunology, including the role of immunotherapy in general and as it pertains to head and neck squamous cell carcinoma. Side effects, resistance mechanisms, and therapeutic monitoring strategies pertaining to immunotherapy are discussed.

Cited by

• Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherapy
• Impact of Epigenetic Regulation on Head and Neck Squamous Cell Carcinoma. [europepmc]
• Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma. [europepmc]
• Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells. [europepmc]
• Molecular biology of oral cavity squamous cell carcinoma. [europepmc]
• Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. [europepmc]
• Increased Tumor Immune Microenvironment CD3+ and CD20+ Lymphocytes Predict a Better Prognosis in Oral Tongue Squamous Cell Carcinoma. [europepmc]
• Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges. [europepmc]
• Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma. [europepmc]
• Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer. [europepmc]
• A novel neutrophil extracellular trap signature to predict prognosis and immunotherapy response in head and neck squamous cell carcinoma. [europepmc]
• PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors' Response and Survival in Advanced Melanoma Patients in Brazil. [europepmc]
• Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability. [europepmc]
• Generating tumor-specific T cells based on a head and neck cancer organoid for adoptive cell therapy. [europepmc]
• Unravelling molecular mechanism of oral squamous cell carcinoma and genetic landscape: an insight into disease complexity, available therapies, and future considerations. [europepmc]
• Chorus line in oral squamous cell carcinoma: How stromal and immune players orchestrate tumor progression (Review). [europepmc]

Related

• Cancer immunotherapy: The past, the present and the future
• Immunotherapy of cancer in 2012
• Wirkmechanismen der Immuntherapie und die Prinzipien des Erfolgs vs. Misserfolgs
• A review of cancer immunotherapy toxicity
• Harnessing the immune system and developing targeted vaccines: overall strategies of leveraging the body’s natural defense mechanisms to enhance cancer treatment